Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
The REGN-COV2 treatment offered to COVID-19 patients have shown good results in reducing the viral load even in patients with not so strong immune system.
Regeneron Pharmaceuticals is going to repurchase $5B of its shares from Sanofi without changing their over-a-decade-long partnership as the race for coronavirus vaccine development intensifies.
